Small molecule inhibitors of RAS proteins with oncogenic mutations

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS proteins function as critical molecular switches in cellular processes.
• Mutations in RAS genes are prevalent oncogenes, driving the development of numerous human cancers.
• Targeting RAS signaling pathways is a significant focus in cancer therapy research.

Purpose of the Study:

• To comprehensively review small molecules that modulate RAS signaling pathways.
• To categorize these molecules based on their distinct mechanisms of action.
• To highlight recent advancements in direct RAS inhibition, including covalent inhibitors.

Main Methods:

• Literature review of small molecules targeting RAS signaling.
• Classification of molecules into four main therapeutic strategies.
• Analysis of drug development progress, including clinical trial status.

Main Results:

• Small molecules targeting RAS can be grouped into four categories: blocking membrane association, stabilizing non-productive complexes, inhibiting RAS-effector interactions, and direct inhibition.
• Direct inhibition strategies, particularly covalent inhibitors, represent a promising and advancing therapeutic frontier.
• Several small molecules targeting RAS signaling have progressed to human clinical trials.

Conclusions:

• Small molecules offer diverse strategies for targeting oncogenic RAS signaling.
• Direct inhibition, especially with covalent compounds, shows significant therapeutic potential for RAS-mutant cancers.
• Continued development of these targeted therapies is crucial for improving outcomes in cancer patients with RAS mutations.